Ursolic acid ameliorates thymic atrophy and hyperglycemia in streptozotocin-nicotinamide-induced diabetic mice

Chemico-Biological Interactions

Volumn 188, Issue 3, 2010, Pages 635-642

  Lee, Jin ^a   Yee, Sung Tae ^a   Kim, Jong Jin ^a   Choi, Myung Sook ^b   Kwon, Eun Young ^b   Seo, Kwon Il ^a   Lee, Mi Kyung ^a  

^a Sunchon National University   (South Korea)

^b Kyungpook National University   (South Korea)

Author keywords

Immune response; Metformin; Non obese type 2 diabetes; Thymus; Ursolic acid

Indexed keywords

AMINOTRANSFERASE; CD19 ANTIGEN; CONCANAVALIN A; GAMMA INTERFERON; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; INTERLEUKIN 6; LEPTIN; LIPOPOLYSACCHARIDE; METFORMIN; NICOTINAMIDE; STREPTOZOCIN; TUMOR NECROSIS FACTOR ALPHA; URSOLIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE ACTIVATION; CD4 CD8 RATIO; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HYPERGLYCEMIA; IMMUNE RESPONSE; IMMUNOMODULATION; INSULIN BLOOD LEVEL; INSULIN TOLERANCE TEST; LOW DRUG DOSE; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN BLOOD LEVEL; STREPTOZOCIN DIABETES; T LYMPHOCYTE ACTIVATION; THYMUS ATROPHY;

ANIMALS; ATROPHY; BLOOD GLUCOSE; BODY WEIGHT; CELL PROLIFERATION; CYTOKINES; DIABETES MELLITUS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HYPERGLYCEMIA; INSULIN; LEPTIN; LYMPHOCYTES; MALE; MICE; MICE, INBRED ICR; NIACINAMIDE; PANCREAS; SPLEEN; THYMUS GLAND; TRANSAMINASES; TRITERPENES;

MUS;

EID: 78149466792     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2010.09.019     Document Type: Article

References (53)

1. Nagaya T., Yoshida H., Takahashi H., Kawai M. Increases in body mass index, even within non-obese levels, raise the risk for Type 2 diabetes mellitus: a follow-up study in a Japanese population. Diabetes Med. 2005, 22:1107-1111.
2. Kim D.J., Song K.E., Park J.W., Cho H.K., Lee K.W., Huh K.B. Clinical characteristics of Korean type 2 diabetic patients in 2005. Diabetes Res. Clin. Pract. 2007, 77S:S252-S257.
3. Vaag A., Lund S.S. Non-obese patients with type 2 diabetes and prediabetic subjects: distinct phenotypes requiring special diabetes treatment and (or) prevention?. Appl. Physiol. Nutr. Metab. 2007, 32(5):912-920.
4. Klover P.J., Mooney R.A. Hepatocytes: critical for glucose homeostasis. Int. J. Biochem. 2004, 36:753-758.
5. DeFronzo R.A., Simonson D., Ferrannini E. Hepatic and peripheral insulin resistance: a common feature of type 2 (non-insulin-dependent) and type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1982, 23:313-319.
6. Gore D.C., Wolf S.E., Herndon D.N., Wolfe R.R. Metformin blunts stress-induced hyperglycemia after thermal injury. J. Trauma 2003, 54:555-561.
7. Deng H.P., Chai J.K. The effects and mechanisms of insulin on systemic inflammatory response and immune cells severe trauma, burn injury, and sepsis. Int. Immunopharmacol. 2005, 9:1251-1259.
8. Marble A, White H.J., Fernald A.T. The nature of the lowered resistance to infection in diabetes mellitus. J. Clin. Invest. 1938, 17:423-430.
9. Calder P.C., Dimitriadis G., Newsholme P. Glucose metabolism in lymphoid and inflammatory cells and tissues. Curr. Opin. Clin. Nutr. Metab. Care 2007, 10(4):531-540.
10. Esper R.J., Vilarino J.O., Machado R.A., Paragano A. Endothelial dysfunction in normal and abnormal glucose metabolism. Adv. Cardiol. 2008, 45:17-43.
11. Ahmad S.F., Khan B., Bani S., Suri K.A., Satti N.K., Qazi G.N. Amelioration of adjuvant-induced arthritis by ursolic acid through altered Th1/Th2 cytokine production. Pharmacol. Res. 2006, 53:233-240.
12. Zhang W., Hong D., Zhou Y., Zhang Y., Shen Q., Li J.Y., Hu L.H., Li J. Ursolic acid and its derivative inhibit protein tyrosine phosphatase 1B, enhancing insulin receptor phosphorylation and stimulating glucose uptake. Biochim. Biophys. Acta 2006, 1760:1505-1512.
13. Jung S.H., Ha Y.J., Shim E.K., Choi S.Y., Jin J.L., Choi H.S.Y., Lee J.R. Insulin-mimetic and insulin-sensitizing activities of a pentacyclic triterpenoid insulin receptor activatior. Biochem. J. 2007, 403:243-250.
14. Jang S.M., Yee S.T., Choi J., Choi M.S., Do G.M., Jeon S.M., Yeo J., Kim M.J., Seo K.I., Lee M.K. Ursolic acid enhances the cellular immune system and pancreatic beta-cell function in streptozotocin-induced diabetic mice fed a high-fat diet. Int. Immunopharmacol. 2009, 9:113-119.
15. Jang S.M., Kim M.J., Choi M.S., Kwon E.Y., Lee M.K. Inhibitory effects of ursolic acid on hepatic polyol pathway and glucose production in streptozotocin-induced diabetic mice. Metab. Clin. Exp. 2010, 59:512-519.
16. Hundal R.S., Krssak M., Dufour S., Laurent D., Lebon V., Chandramouli V., Inzucchi S.E., Schumann W.C., Petersen K.F., Landau B.R., Shulman G.I. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 2000, 49:2063-2069.
17. Ong C.R., Twigg S.M., Molyneaux L.M., Yue D.K., Constantino M.I. Long-term efficacy of metformin therapy in nonobese individuals with type 2 diabetes. Diabetes Care 2006, 29:2361-2364.
18. Nakamura T., Terajima T., Ogata T., Ueno K., Hashimoto N., Ono K., Yano S. Establishment and pathophysiological characterization of Type 2 diabetic mouse model produced by streptozotocin and nicotinamide. Biol. Pharm. Bull. 2006, 29(6):1167-1174.
19. American Institute of Nutrition Report of Ad Hoc committee on standards for nutritional studies. J. Nutr. 1980, 110:1717-1726.
20. American Institute of Nutrition Report of the American Institute of Nutrition. Ad Hoc committee on standards for nutritional studies. J. Nutr. 1977, 107:1340-1348.
21. Glueck C.J., Aregawi D., Winiarska M., Agloria M., Luo G., Sieve L., Wang P. Metformin-diet ameliorates coronary heart disease risk factors and facilitates resumption of regular menses in adolescents with polycystic ovary syndrome. J. Pediatr. Endocrinol. Metab. 2006, 19(6):831-842.
22. Suwa M., Egashira T., Nakano H., Sasaki H., Kumagai S. Metformin increases the PGC-1α protein and oxidative enzyme activities possibly via AMPK phosphorylation in skeletal muscle in vivo. J. Appl. Physiol. 2006, 101:1685-1692.
23. Shima K., Zhu M., Noma Y., Mizuno A., Murakami T., Sano T., Kuwajima M. Exercise training in Otsuka Long-Evans Tokushima Fatty rat, a model of spontaneous non-insulin-dependent diabetes mellitus: effects on the B-cell mass, insulin content and fibrosis in the pancreas. Diabetes Res. Clin. Pract. 1997, 35:11-19.
24. Tuomi T., Carlsson A., Li H., Isomaa B., Miettinen A., Nilsson A., Nissen M., Ehrnstrom B.O., Forsen B., Snickars B., Lahti K., Forsblom C., Saloranta C., Taskinen M.R., Groop L.C. Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 1999, 48:150-157.
25. Tabata T., Okuna Y., Fujni S., Kimura S., Kinoshita Y. Maturational impairment of thymic lymphocytes in streptozotocin-induced diabetes in rats. Cell Immunol. 1984, 89:250-258.
26. Nichols W.K., Vann L.L., Spellman J.B. Streptozotocin effects on T lymphocytes and bone marrow cells. Clin. Exp. Immunol. 1981, 46:627-632.
27. Wellhausen S.R. Defination of streptozotocin toxicity for primary lymphoidal tissues. Diabetes 1986, 35:1404-1411.
28. Scott P., Kamfmann S.H. The role of T-cell subsets and cytokines in the regulation of infection. Immunol. Today 1991, 12(10):346-348.
29. Hanlon P.R., Robbins M.G., Scholl C., Barnes D.M. Aqueous extracts from dietary supplements influence the production of inflammatory cytokines in immortalized and primary T lymphocytes. BMC Complement. Altern. Med. 2009, 9:51-61.
30. Solano M.E., Sander V., Wald M.R., Motta A.B. Dehydroepiandrosterone and metformin regulate proliferation of murine T lymphocytes. Clin. Exp. Immunol. 2008, 153:289-296.
31. Fernandez-Real J.M., Pickup J.D. Innate immunity, insulin resistance and type 2 diabetes. Trends Endocrinol. Metabol. 2007, 19:10-16.
32. Dworacka M., Winiarska H., Borowska M., Abramczyk M., Bobkiewicz-Kozlowska T., Dworacki G. Pro-atherogenic alterations in T-lymphocyte subpopulations related to acute hyperglycaemia in type 2 diabetic patients. Circ. J. 2007, 71:962-967.
33. Takahiro T., Yoshinobu M., Takahiro K., Kumi S., Jiro I. Correlations of sleep disturbance with the immune system in type 2 diabetes mellitus. Diabetes Res. Clin. Pract. 2009, 85:286-292.
34. Thorvaldson L., Stalhammar S., Sandler S. Effects of a diabetes-like environment in vitro on cytokine production by mouse splenocytes. Cytokine 2008, 43:93-97.
35. Suh N., Honda T., Finlay H.J., Barchowsky A., Williams C., Benoit N.E., Xie Q.W., Nathan C., Gribble G.W., Sporn M.B. Novel triterpenoids suppress inducible nitric oxide synthase (iNOS) and inducible cyclooxygenase (COX-2) in mouse macrophages. Cancer Res. 1998, 58:717-723.
36. Tokuda H., Ohigashi H., Koshimizu K., Ito Y. Inhibitory effects of ursolic and oleanolic acid on skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate. Cancer Lett. 1986, 33:279-285.
37. P.R. Nagib, J. Gameiro, L. Guilherme Stivanin-Silva, M. Sueli Parreira de Arruda, D. Maria Serra Villa-Verde, W. Savino, L. Verinaud, Thymic microenvironmental alterations in experimentally induced diabetes, Immunobiology, in press, doi:10.1016/j.imbio.2010.02.001.
38. Barreto E.O., Riederer I., Arantes A.C., Carvalho V.F., Farias-Filho F.A., Cordeiro R.S.B., Martins M.A., Savino W., Silva P.M.R. Thymus involution in alloxan diabetes: analysis of mast cells. Mem. Inst. Oswaldo Cruz 2005, 100(Suppl. 1):127-130.
39. Dagistanli F.K., Duman B.S., Ozturk M. Protective effects of a calcium channel blocker on apoptosis in thymus of neonatal STZ-diabetic rats. Acta Histochem. 2005, 107:207-214.
40. Elmas C., Erdogan D., Take G., Ozogul C., Nacar A., Koksal M. Ultrastructure of the thymus in diabetes mellitus and starvation. Adv. Ther. 2008, 25:67-76.
41. Savino W. The thymus is a common target organ in infectious diseases. PLoS Pathog. 2006, 2:472-483.
42. Andrade C.F., Gameiro J., Nagib P.R., Carbalho B.O., Talaisys R.L., Costa F.T., Verinaud L. thymic alterations in Plasmodium berghei-infected mice. Cell Immunol. 2008, 253:1-4.
43. Singer A, Bosselut R. CD4/CD8 coreceptors in thymocyte development, selection, and lineage commitment: analysis of the CD4/CD8 lineage decision. Adv. Immunol. 2004, 83:91-131.
44. Gruver A.L., Sempowski G.D. Cytokines, leptin, and stress-induced thymic atrophy. J. Leukoc. Biol. 2008, 84:915-923.
45. Velloso L.A., Savino W., Mansour E. Leptin action in the thymus. Ann. N.Y. Acad. Sci. 2009, 1156:29-34.
46. Savino W., Dardenne M., Velloso L.A., Silva-Barvosa S.D. The thymus is a common target in malnutrition and infection. Br. J. Nutr. 2007, 98:S11-S16.
47. Bernotiene E., Palmer G., Gabay C. The role of leptin in innate and adaptive immune responses. Arthritis Res. Ther. 2006, 8:217-226.
48. Ellger B., Debaveye Y., Vanhorebeek I., Langouche L., Giulietti A., Van Etten E., Herijgers P., Mathieu C., Van den Berghe G. Survival benefits of intensive insulin therapy in critical illness: impact of maintaining normoglycemia versus glycemia-independent actions of insulin. Diabetes 2006, 55(4):1096-1105.
49. Yoshida T., Okuno A., Tanaka J., Takahashi K., Nakashima R., Kanda S., Ogawa J., Hagisawa Y., Fujiwara T. Metformin primarily decreases plasma glucose not by gluconeogenesis suppression but by activating glucose utilization in a non-obese type 2 diabetes Goto-Kakizaki rats. Eur. J. Pharmacol. 2009, 623:141-147.
50. Issad T., Penicaud L., Ferre P., Kande J., Baudon M.A., Girard J. Effects of fasting on tissue glucose utilization in conscious resting rats. Biochem. J. 1987, 246:241-244.
51. Liu J. Pharmacology of oleanolic acid and ursolic acid. J. Ethnopharmacol. 1995, 49:57-68.
52. Jeschke M.G., Rensing H., Klein D., Schubert T., Mautes A.E., Bolder U., Croner R.S. Insulin prevents liver damage and preserves liver function in lipopolysaccharide-induced endotoxemic rats. J. Hepatol. 2005, 42(6):870-879.
53. Ikeda Y., Murakami A., Ohigashi H. Ursolic acid: an anti-and pro-inflammatory triterpenoid. Mol. Nutr. Food Res. 2008, 52:26-42.